Navigation Links
OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
Date:7/24/2009

BOTHELL, WA and VANCOUVER, July 24 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it has completed its registered direct offering, previously announced on July 20, 2009, of 475,000 shares of its common stock to institutional investors at a price of $20.00 per share, for gross proceeds to the Company of approximately $9.5 million. The $20 offering price represented a 3.5% discount to the closing price on July 17, 2009, the last trading day prior to announcement. After deducting the estimated offering expenses payable by the Company, the net proceeds are expected to be approximately $9.4 million.

The Company plans to use the net proceeds from the offering primarily for manufacturing readiness activities and general corporate purposes.

The shares of common stock offered by OncoGenex in this transaction were offered and sold pursuant to OncoGenex's existing shelf registration statement on Form S-3, which was declared effective by the Securities and Exchange Commission on July 17, 2009. There was no placement agent or underwriter in this transaction.

Copies of the prospectus supplement and accompanying base prospectus relating to this offering may be obtained at the Securities and Exchange Commission's web site at http://www.sec.gov, or from OncoGenex Pharmaceuticals, Inc., 1522 217th Pl. SE, Suite 100, Bothell, WA 98021-7617, Attention: Chief Financial Officer.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy the common stock of OncoGenex, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About OncoGenex
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
2. OncoGenex Pharmaceuticals Added to Russell Indexes
3. OncoGenex Pharmaceuticals Files Shelf Registration Statement
4. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
5. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
6. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
7. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
8. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
9. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
10. OncoGenex Reports First Quarter Financial Results
11. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... April 17, 2015 BellBrook Labs ... marketing support for the powerful Orthogonal Pooled Screening ... Genomics Center at the Lankenau Institute for Medical ... is to measurably improve successful drug discovery outcomes ... offering rare, drug-like libraries available nowhere else, coupled ...
(Date:4/16/2015)... April 16, 2015 Capillus, LLC ... and physician network in Europe and Asia. The ... appointed Fernando Bermúdez, former Business Development Director of ... industry veteran, Mr. Bermúdez’s professional achievements include increasing ... Spain, while also penetrating the Portuguese marketplace with ...
(Date:4/16/2015)... 16, 2015 OncoTAb, Inc., ... (UNC Charlotte) spin-out company, announced today the appointment ... M.D., as Chief Operating Officer (COO). Cooper brings ... in developing clinical diagnostic and biotechnology platforms in ... , Cooper’s extensive career transcends the field of ...
(Date:4/16/2015)... GUELPH, ON , April 16, 2015 /CNW/ - Bioenterprise ... opening its newest office in Charlottetown ... with the Prince Edward Island ADAPT Council for the ... are looking forward to working with PEI ADAPT.  They ... Maritimes for more than a decade," explains Dave ...
Breaking Biology Technology:BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2OncoTAb Names Dr. David L. Cooper as COO 2Bioenterprise Corporation Expands into the Maritimes 2
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... While radiation treatments deliver precise doses of high-energy ... to shrink tumors, oncologists have become increasingly concerned ... treatments to nerves responsible for upper body mobility. ... UC Davis Cancer Center researchers have taken the ...
... Department of Statistics and Centre for Complexity Science have ... the complex cell interactions that lead to cancer and ... such as Facebook for useful insights. An approach ... gain an understanding of a range of systems with ...
... As polar bears adapt to a warming Arctica frozen seascape ... unlikely source: snow goose eggs. New calculations show that changes ... nesting near the western Hudson Bay could provide at least ... new analysis appears in Polar Biology . "Over ...
Cached Biology News:UC Davis team refines cancer treatments to reduce potential nerve damage 2New tool could unpick complex cancer causes and help sociologists mine Facebook 2Goose eggs may help polar bears weather climate change 2
Prepared in distilled water....
in vitro Translation, Accessory Products...
... The Zero Blunt TOPO ... Sequencing is designed for ... of blunt-end PCR products. ... 5-minute TOPO Cloning and ...
... The Zero Blunt ... for Sequencing is designed ... sequencing of blunt-end PCR ... provides 5-minute TOPO Cloning ...
Biology Products: